Cargando…
Establishment of an ELISA-based primary antiviral screen and plaque reduction based confirmatory assay for evaluation of compounds against the filovirus ebola under maximum biological containment conditions (BL-4) : J.W. Huggins, Z.X. Zhang and T.P. Monath. Department of Antiviral Studies, Virology Division, U.S. Army Medical Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, 21701-5011, USA
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Published by Elsevier B.V.
1990
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134216/ http://dx.doi.org/10.1016/0166-3542(90)90114-M |
| _version_ | 1783517792408961024 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7134216 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 1990 |
| publisher | Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71342162020-04-08 Establishment of an ELISA-based primary antiviral screen and plaque reduction based confirmatory assay for evaluation of compounds against the filovirus ebola under maximum biological containment conditions (BL-4) : J.W. Huggins, Z.X. Zhang and T.P. Monath. Department of Antiviral Studies, Virology Division, U.S. Army Medical Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, 21701-5011, USA Antiviral Res Abstract Poster session I Synthesis, in vitro evaluation, immunomodulators Published by Elsevier B.V. 1990-04 2002-11-14 /pmc/articles/PMC7134216/ http://dx.doi.org/10.1016/0166-3542(90)90114-M Text en Copyright © 1990 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Abstract Poster session I Synthesis, in vitro evaluation, immunomodulators Establishment of an ELISA-based primary antiviral screen and plaque reduction based confirmatory assay for evaluation of compounds against the filovirus ebola under maximum biological containment conditions (BL-4) : J.W. Huggins, Z.X. Zhang and T.P. Monath. Department of Antiviral Studies, Virology Division, U.S. Army Medical Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, 21701-5011, USA |
| title | Establishment of an ELISA-based primary antiviral screen and plaque reduction based confirmatory assay for evaluation of compounds against the filovirus ebola under maximum biological containment conditions (BL-4) : J.W. Huggins, Z.X. Zhang and T.P. Monath. Department of Antiviral Studies, Virology Division, U.S. Army Medical Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, 21701-5011, USA |
| title_full | Establishment of an ELISA-based primary antiviral screen and plaque reduction based confirmatory assay for evaluation of compounds against the filovirus ebola under maximum biological containment conditions (BL-4) : J.W. Huggins, Z.X. Zhang and T.P. Monath. Department of Antiviral Studies, Virology Division, U.S. Army Medical Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, 21701-5011, USA |
| title_fullStr | Establishment of an ELISA-based primary antiviral screen and plaque reduction based confirmatory assay for evaluation of compounds against the filovirus ebola under maximum biological containment conditions (BL-4) : J.W. Huggins, Z.X. Zhang and T.P. Monath. Department of Antiviral Studies, Virology Division, U.S. Army Medical Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, 21701-5011, USA |
| title_full_unstemmed | Establishment of an ELISA-based primary antiviral screen and plaque reduction based confirmatory assay for evaluation of compounds against the filovirus ebola under maximum biological containment conditions (BL-4) : J.W. Huggins, Z.X. Zhang and T.P. Monath. Department of Antiviral Studies, Virology Division, U.S. Army Medical Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, 21701-5011, USA |
| title_short | Establishment of an ELISA-based primary antiviral screen and plaque reduction based confirmatory assay for evaluation of compounds against the filovirus ebola under maximum biological containment conditions (BL-4) : J.W. Huggins, Z.X. Zhang and T.P. Monath. Department of Antiviral Studies, Virology Division, U.S. Army Medical Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, 21701-5011, USA |
| title_sort | establishment of an elisa-based primary antiviral screen and plaque reduction based confirmatory assay for evaluation of compounds against the filovirus ebola under maximum biological containment conditions (bl-4) : j.w. huggins, z.x. zhang and t.p. monath. department of antiviral studies, virology division, u.s. army medical institute of infectious diseases, fort detrick, frederick, maryland, 21701-5011, usa |
| topic | Abstract Poster session I Synthesis, in vitro evaluation, immunomodulators |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134216/ http://dx.doi.org/10.1016/0166-3542(90)90114-M |